Zilovertamab vedotin,rituximab
oncternal therapeutics,merck
['lymphoma', 'dlbcl', 'lymsm', ' vedo', 'zilovertamab']
muhit zcan, md, on dlbcl: now recruiting previously untreated patients for a study of zilovertamab vedotin plus chemotherapy #lymsm #lymphoma #hematology #asco23
News and views from the world of clinical oncology and hematology